Q4 EPS Estimates for Sanuwave Health Reduced by Analyst

Key Points

• Analyst Northland Capmk has reduced Q4 2025 EPS estimates for Sanuwave Health from $0.20 to $0.06 per share, while maintaining a "Strong-Buy" rating on the stock.
• Sanuwave Health recently reported a quarterly earnings surprise, posting $0.01 earnings per share compared to the consensus estimate of ($0.09), along with revenue slightly above estimates at $10.16 million.
• Institutional investors have shown significant interest, with several acquiring new stakes, while 42.53% of the stock is held by hedge funds and other institutional investors.

Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) - Equities researchers at Northland Capmk cut their Q4 2025 earnings estimates for Sanuwave Health in a report released on Tuesday, October 7th. Northland Capmk analyst C. Byrnes now expects that the company will earn $0.06 per share for the quarter, down from their previous forecast of $0.20. Northland Capmk has a "Strong-Buy" rating on the stock. Northland Capmk also issued estimates for Sanuwave Health's FY2026 earnings at $0.75 EPS.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.10. The firm had revenue of $10.16 million for the quarter, compared to the consensus estimate of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Several other brokerages also recently weighed in on SNWV. Wall Street Zen raised shares of Sanuwave Health from a "hold" rating to a "buy" rating in a report on Friday, October 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Sanuwave Health in a report on Wednesday. Roth Capital set a $53.00 price target on shares of Sanuwave Health and gave the stock a "buy" rating in a report on Tuesday. Finally, Northland Securities assumed coverage on shares of Sanuwave Health in a report on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $54.00.

Sanuwave Health Trading Down 2.1%

Shares of SNWV opened at $31.33 on Thursday. The firm has a market cap of $268.44 million, a PE ratio of -3.80 and a beta of 1.33. Sanuwave Health has a 1-year low of $5.63 and a 1-year high of $46.58. The firm has a fifty day simple moving average of $37.69 and a two-hundred day simple moving average of $33.86.

Institutional Investors Weigh In On Sanuwave Health

Several institutional investors have recently modified their holdings of SNWV. Strategic Investment Solutions Inc. IL acquired a new stake in Sanuwave Health during the 1st quarter worth $47,000. Solas Capital Management LLC purchased a new stake in Sanuwave Health during the first quarter worth about $20,658,000. AWM Investment Company Inc. purchased a new stake in shares of Sanuwave Health in the first quarter valued at about $18,153,000. Goldman Sachs Group Inc. acquired a new position in Sanuwave Health during the first quarter worth approximately $337,000. Finally, Evernest Financial Advisors LLC acquired a new stake in shares of Sanuwave Health in the second quarter worth $823,000. 42.53% of the stock is owned by hedge funds and other institutional investors.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.